PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Metastatic Breast Cancer
Related studies linked through entity extraction aliases.
A Physical Activity Program to Improve Quality of Life and Reduce Fatigue in Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- NA
Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1
Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy
- Status
- UNKNOWN
- Phase
- PHASE2
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
- Status
- RECRUITING
- Phase
- PHASE1
Dose-finding Study of BP-C1 in Patients With Stage IV Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)
- Status
- TERMINATED
- Phase
- PHASE1
Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
D4 Choline Breast PET/CT
- Status
- COMPLETED
- Phase
- N/A
Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.
- Status
- WITHDRAWN
- Phase
- PHASE2
Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Feasibility of Integrating the Outcomes4Me Smartphone Navigation Application Into the Care Management of Breast Cancer Patients
- Status
- UNKNOWN
- Phase
- NA
Genetic Characteristics of Metastatic Breast Cancer Patients
- Status
- UNKNOWN
- Phase
- NA
Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy
- Status
- COMPLETED
- Phase
- N/A
Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE1
A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel
- Status
- WITHDRAWN
- Phase
- PHASE1
Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression
- Status
- TERMINATED
- Phase
- PHASE2
Τreatment Standards and Outcomes of Patients With ER/PR Positive, HER2-negative Metastatic Breast Cancer
- Status
- UNKNOWN
- Phase
- N/A
Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2